Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats
To evaluate the ability of cilostazol, an antiplatelet and vasodilating agent, to promote axonal regeneration in streptozotocin-induced diabetic rats, the time until beginning of regeneration (initial delay) and the axonal regeneration rate of the sciatic nerve were estimated using the pinch test, a...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 1998-07, Vol.352 (2), p.171-178 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 2 |
| container_start_page | 171 |
| container_title | European journal of pharmacology |
| container_volume | 352 |
| creator | Yamamoto, Yasuchika Yasuda, Yoshinobu Kimura, Yukio Yoshiaki Komiya |
| description | To evaluate the ability of cilostazol, an antiplatelet and vasodilating agent, to promote axonal regeneration in streptozotocin-induced diabetic rats, the time until beginning of regeneration (initial delay) and the axonal regeneration rate of the sciatic nerve were estimated using the pinch test, and ornithine decarboxylase activity was measured in dorsal root ganglia. At 5 weeks of diabetes, axonal regeneration rate remained unchanged but the initial delay was prolonged and ornithine decarboxylase induction was delayed in diabetic rats compared with those in normal rats. Cilostazol had little effect on these parameters in normal or diabetic rats. At 10 weeks of diabetes, diabetic rats showed both prolongation of initial delay and a decrease in axonal regeneration rate. Cilostazol markedly increased axonal regeneration rate in diabetic rats. Ornithine decarboxylase induction following nerve injury disappeared almost completely in diabetic rats but was maintained by cilostazol treatment. The effect of cilostazol in diabetic rats is thought to be mediated through its preventive effect on circulatory disorders. The active site of the drug appears to be early processes in nerve regeneration before ornithine decarboxylase induction. Further, the results suggest that the both axonal regeneration and this induction are sensitive to circulatory defects in diabetes. |
| doi_str_mv | 10.1016/S0014-2999(98)00356-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73879123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299998003562</els_id><sourcerecordid>73879123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-df75804c97857b7a9124c0b23b311813b62cfd5a2231685da5b8a5bdd5f769fd3</originalsourceid><addsrcrecordid>eNqFkU1rXCEUhqWkpNM0PyHgIoQWcls_xquuQgnpBwS6SLIWrx6DwblO1Emb_vqazDDbgnLgPc9ReUTohJLPlNDxyw0hdDkwrfVHrT4RwsU4sDdoQZXUA5GUHaDFHnmH3tf6QAgRmolDdKglHblgC5SuQgDXKs4Bu5hybfZvTufYzn21uE62QYKG7T3M7RznHv_Js024QE-g2BZ7FnJK-Xec73GPngDH-WFTnnvBPtoJWnS4k_UDehtsqnC8q0fo7tvV7eWP4frX95-XX68HJ4hsgw9SKLJ0WiohJ2k1ZUtHJsYnTqmifBqZC15YxjgdlfBWTKpv70WQow6eH6Gz7bnrkh83UJtZxeogJTtD3lQjeXdEGe-g2IKu5FoLBLMucWXLs6HEvFg2r5bNi0KjlXm1bFifO9ldsJlW4PdTO629f7rr2-psCsXOLtY9xrjQSowdu9hi0GU8RSimugizAx9L_xTjc_zPQ_4BTI2aNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73879123</pqid></control><display><type>article</type><title>Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Yamamoto, Yasuchika ; Yasuda, Yoshinobu ; Kimura, Yukio ; Yoshiaki Komiya</creator><creatorcontrib>Yamamoto, Yasuchika ; Yasuda, Yoshinobu ; Kimura, Yukio ; Yoshiaki Komiya</creatorcontrib><description>To evaluate the ability of cilostazol, an antiplatelet and vasodilating agent, to promote axonal regeneration in streptozotocin-induced diabetic rats, the time until beginning of regeneration (initial delay) and the axonal regeneration rate of the sciatic nerve were estimated using the pinch test, and ornithine decarboxylase activity was measured in dorsal root ganglia. At 5 weeks of diabetes, axonal regeneration rate remained unchanged but the initial delay was prolonged and ornithine decarboxylase induction was delayed in diabetic rats compared with those in normal rats. Cilostazol had little effect on these parameters in normal or diabetic rats. At 10 weeks of diabetes, diabetic rats showed both prolongation of initial delay and a decrease in axonal regeneration rate. Cilostazol markedly increased axonal regeneration rate in diabetic rats. Ornithine decarboxylase induction following nerve injury disappeared almost completely in diabetic rats but was maintained by cilostazol treatment. The effect of cilostazol in diabetic rats is thought to be mediated through its preventive effect on circulatory disorders. The active site of the drug appears to be early processes in nerve regeneration before ornithine decarboxylase induction. Further, the results suggest that the both axonal regeneration and this induction are sensitive to circulatory defects in diabetes.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(98)00356-2</identifier><identifier>PMID: 9716352</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Antiplatelet vasodilating agent ; Axonal regeneration ; Axons - drug effects ; Biological and medical sciences ; Blood Glucose - analysis ; Body Weight ; Cardiovascular system ; Cilostazol ; Diabetes Mellitus, Experimental - complications ; Diabetic Neuropathies - drug therapy ; Diabetic Neuropathies - enzymology ; Enzyme Induction ; Male ; Medical sciences ; Nerve injury ; Nerve Regeneration - drug effects ; Ornithine decarboxylase ; Ornithine Decarboxylase - biosynthesis ; Pharmacology. Drug treatments ; Phosphodiesterase inhibitor ; Platelet Aggregation Inhibitors - pharmacology ; Platelet Aggregation Inhibitors - therapeutic use ; Rats ; Rats, Wistar ; Sciatic Nerve - physiopathology ; Streptozocin ; Streptozotocin diabetic rat ; Tetrazoles - pharmacology ; Tetrazoles - therapeutic use ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>European journal of pharmacology, 1998-07, Vol.352 (2), p.171-178</ispartof><rights>1998 Elsevier Science B.V.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-df75804c97857b7a9124c0b23b311813b62cfd5a2231685da5b8a5bdd5f769fd3</citedby><cites>FETCH-LOGICAL-c507t-df75804c97857b7a9124c0b23b311813b62cfd5a2231685da5b8a5bdd5f769fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0014-2999(98)00356-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2359856$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9716352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamamoto, Yasuchika</creatorcontrib><creatorcontrib>Yasuda, Yoshinobu</creatorcontrib><creatorcontrib>Kimura, Yukio</creatorcontrib><creatorcontrib>Yoshiaki Komiya</creatorcontrib><title>Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>To evaluate the ability of cilostazol, an antiplatelet and vasodilating agent, to promote axonal regeneration in streptozotocin-induced diabetic rats, the time until beginning of regeneration (initial delay) and the axonal regeneration rate of the sciatic nerve were estimated using the pinch test, and ornithine decarboxylase activity was measured in dorsal root ganglia. At 5 weeks of diabetes, axonal regeneration rate remained unchanged but the initial delay was prolonged and ornithine decarboxylase induction was delayed in diabetic rats compared with those in normal rats. Cilostazol had little effect on these parameters in normal or diabetic rats. At 10 weeks of diabetes, diabetic rats showed both prolongation of initial delay and a decrease in axonal regeneration rate. Cilostazol markedly increased axonal regeneration rate in diabetic rats. Ornithine decarboxylase induction following nerve injury disappeared almost completely in diabetic rats but was maintained by cilostazol treatment. The effect of cilostazol in diabetic rats is thought to be mediated through its preventive effect on circulatory disorders. The active site of the drug appears to be early processes in nerve regeneration before ornithine decarboxylase induction. Further, the results suggest that the both axonal regeneration and this induction are sensitive to circulatory defects in diabetes.</description><subject>Animals</subject><subject>Antiplatelet vasodilating agent</subject><subject>Axonal regeneration</subject><subject>Axons - drug effects</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - analysis</subject><subject>Body Weight</subject><subject>Cardiovascular system</subject><subject>Cilostazol</subject><subject>Diabetes Mellitus, Experimental - complications</subject><subject>Diabetic Neuropathies - drug therapy</subject><subject>Diabetic Neuropathies - enzymology</subject><subject>Enzyme Induction</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nerve injury</subject><subject>Nerve Regeneration - drug effects</subject><subject>Ornithine decarboxylase</subject><subject>Ornithine Decarboxylase - biosynthesis</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphodiesterase inhibitor</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Sciatic Nerve - physiopathology</subject><subject>Streptozocin</subject><subject>Streptozotocin diabetic rat</subject><subject>Tetrazoles - pharmacology</subject><subject>Tetrazoles - therapeutic use</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1rXCEUhqWkpNM0PyHgIoQWcls_xquuQgnpBwS6SLIWrx6DwblO1Emb_vqazDDbgnLgPc9ReUTohJLPlNDxyw0hdDkwrfVHrT4RwsU4sDdoQZXUA5GUHaDFHnmH3tf6QAgRmolDdKglHblgC5SuQgDXKs4Bu5hybfZvTufYzn21uE62QYKG7T3M7RznHv_Js024QE-g2BZ7FnJK-Xec73GPngDH-WFTnnvBPtoJWnS4k_UDehtsqnC8q0fo7tvV7eWP4frX95-XX68HJ4hsgw9SKLJ0WiohJ2k1ZUtHJsYnTqmifBqZC15YxjgdlfBWTKpv70WQow6eH6Gz7bnrkh83UJtZxeogJTtD3lQjeXdEGe-g2IKu5FoLBLMucWXLs6HEvFg2r5bNi0KjlXm1bFifO9ldsJlW4PdTO629f7rr2-psCsXOLtY9xrjQSowdu9hi0GU8RSimugizAx9L_xTjc_zPQ_4BTI2aNQ</recordid><startdate>19980710</startdate><enddate>19980710</enddate><creator>Yamamoto, Yasuchika</creator><creator>Yasuda, Yoshinobu</creator><creator>Kimura, Yukio</creator><creator>Yoshiaki Komiya</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980710</creationdate><title>Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats</title><author>Yamamoto, Yasuchika ; Yasuda, Yoshinobu ; Kimura, Yukio ; Yoshiaki Komiya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-df75804c97857b7a9124c0b23b311813b62cfd5a2231685da5b8a5bdd5f769fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antiplatelet vasodilating agent</topic><topic>Axonal regeneration</topic><topic>Axons - drug effects</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - analysis</topic><topic>Body Weight</topic><topic>Cardiovascular system</topic><topic>Cilostazol</topic><topic>Diabetes Mellitus, Experimental - complications</topic><topic>Diabetic Neuropathies - drug therapy</topic><topic>Diabetic Neuropathies - enzymology</topic><topic>Enzyme Induction</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nerve injury</topic><topic>Nerve Regeneration - drug effects</topic><topic>Ornithine decarboxylase</topic><topic>Ornithine Decarboxylase - biosynthesis</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphodiesterase inhibitor</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Sciatic Nerve - physiopathology</topic><topic>Streptozocin</topic><topic>Streptozotocin diabetic rat</topic><topic>Tetrazoles - pharmacology</topic><topic>Tetrazoles - therapeutic use</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamamoto, Yasuchika</creatorcontrib><creatorcontrib>Yasuda, Yoshinobu</creatorcontrib><creatorcontrib>Kimura, Yukio</creatorcontrib><creatorcontrib>Yoshiaki Komiya</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamamoto, Yasuchika</au><au>Yasuda, Yoshinobu</au><au>Kimura, Yukio</au><au>Yoshiaki Komiya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1998-07-10</date><risdate>1998</risdate><volume>352</volume><issue>2</issue><spage>171</spage><epage>178</epage><pages>171-178</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>To evaluate the ability of cilostazol, an antiplatelet and vasodilating agent, to promote axonal regeneration in streptozotocin-induced diabetic rats, the time until beginning of regeneration (initial delay) and the axonal regeneration rate of the sciatic nerve were estimated using the pinch test, and ornithine decarboxylase activity was measured in dorsal root ganglia. At 5 weeks of diabetes, axonal regeneration rate remained unchanged but the initial delay was prolonged and ornithine decarboxylase induction was delayed in diabetic rats compared with those in normal rats. Cilostazol had little effect on these parameters in normal or diabetic rats. At 10 weeks of diabetes, diabetic rats showed both prolongation of initial delay and a decrease in axonal regeneration rate. Cilostazol markedly increased axonal regeneration rate in diabetic rats. Ornithine decarboxylase induction following nerve injury disappeared almost completely in diabetic rats but was maintained by cilostazol treatment. The effect of cilostazol in diabetic rats is thought to be mediated through its preventive effect on circulatory disorders. The active site of the drug appears to be early processes in nerve regeneration before ornithine decarboxylase induction. Further, the results suggest that the both axonal regeneration and this induction are sensitive to circulatory defects in diabetes.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>9716352</pmid><doi>10.1016/S0014-2999(98)00356-2</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 1998-07, Vol.352 (2), p.171-178 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73879123 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Animals Antiplatelet vasodilating agent Axonal regeneration Axons - drug effects Biological and medical sciences Blood Glucose - analysis Body Weight Cardiovascular system Cilostazol Diabetes Mellitus, Experimental - complications Diabetic Neuropathies - drug therapy Diabetic Neuropathies - enzymology Enzyme Induction Male Medical sciences Nerve injury Nerve Regeneration - drug effects Ornithine decarboxylase Ornithine Decarboxylase - biosynthesis Pharmacology. Drug treatments Phosphodiesterase inhibitor Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Rats Rats, Wistar Sciatic Nerve - physiopathology Streptozocin Streptozotocin diabetic rat Tetrazoles - pharmacology Tetrazoles - therapeutic use Vasodilator agents. Cerebral vasodilators |
| title | Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A15%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20cilostazol,%20an%20antiplatelet%20agent,%20on%20axonal%20regeneration%20following%20nerve%20injury%20in%20diabetic%20rats&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Yamamoto,%20Yasuchika&rft.date=1998-07-10&rft.volume=352&rft.issue=2&rft.spage=171&rft.epage=178&rft.pages=171-178&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(98)00356-2&rft_dat=%3Cproquest_cross%3E73879123%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73879123&rft_id=info:pmid/9716352&rft_els_id=S0014299998003562&rfr_iscdi=true |